Publishing holiday for President's Day

Maureen Martino, FierceBiotech Managing EditorDespite a blizzard that paralyzed much of the East Coast (and kept Fierce's DC- and Philadelphia-based editors snowed in), it was a busy week for FierceBiotech. John Carroll (twitter) made it to New York for the Annual BIO CEO & Investor meeting, where he spoke with BIO president and CEO Jim Greenwood about the narrowing path for healthcare reform and what can be done to salvage the 12-year umbrella of data exclusivity. Also at the conference, CEOs from Acorda, Orexigen, Medivation and Dendreon were on hand to tout their companies' up-and-coming therapies.

On Wednesday FiercePharma took a look at the biggest patent expirations in 2010, which include blockbusters like Lipitor, Levaquin and Flomax. And in case you missed it, FierceBiotech chronicled the top 10 biopharma deals of 2009 last week. In the coming days, keep a look-out for our annual report on the biggest VC deals of the year, which highlights some of the most innovative companies with promising new therapies in their pipelines. A few of them could be future 2010 Fierce 15 winners.

We won't be publishing this coming Monday in honor of President's Day. FierceBiotech will be back on Tuesday, February 16th. Enjoy the long weekend. - Maureen Martino (twitter | email)

Suggested Articles

Insitro picked up $143 million to build out its technology, pursue new targets and advance treatments for genetically defined patient groups.

Generation Bio filed for a $215 million IPO to advance a pair of gene therapies for liver disease and push one of them into the clinic.

The IPO will push Avidity's lead muscle disorder program through IND-enabling studies and into the clinic in 2021.